Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-04

Clinical Trial Update: Nevanimibe HCl for the Treatment of Classic CAH [Phase 2]

View source ↗

Summary

A Phase 2 trial of nevanimibe HCl for congenital adrenal hyperplasia was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nevanimibe HCl (nevanimibe hydrochloride)

Snippet

Sponsor: Millendo Therapeutics US, Inc. | Conditions: Congenital Adrenal Hyperplasia | Phase 2 | Status: TERMINATED | Results posted: 2021-03-04